Sun Life's U.S. Disability Wake-Up Call

Underlying EPS rose 10%, but a sharp LTD claims spike is testing the 'repriceable' promise while GreenOak integration and MFS outflows muddy the capital-return story.

SLF · Earnings Call · 2026-11-05

The Quarter That Split in Two

Sun Life's third quarter looked, on the surface, like a reaffirmation of the diversified-insurer model: underlying net income of $1.146 billion, underlying EPS of $2.05 (up 10%), an ROE of 19%, and a LICAT ratio of 142% that remains industry-leading. Canada grew 6%, Asia grew 8% in constant currency, and U.S. stop-loss delivered a 32% jump in U.S. underlying earnings to $141 million. Management even raised the quarterly dividend by $0.04 to $1.00. But the reported numbers told a messier story: reported net income fell to $785 million from $1.1 billion a year ago, hit by unfavorable market-related impacts, GreenOak integration and restructuring costs, and Bell Partners acquisition costs. The real fracture, however, was inside U.S. Employee Benefits, where experience turned sharply negative. David Healy did not sugarcoat it: “we have seen elevated LTD claims in the quarter. They were both -- we saw them in terms of incidence, but also higher severity of those claims as well. And it was consistent with what we're seeing being reported from other industry competitors.” — David Healy, Senior Executive, Head of U.S. Health and Risk Solutions · 2026-11-05 That 'consistent with the industry' phrase is doing a lot of work. It transforms a company-specific miss into a sector-wide cycle — and, management argues, a repricing opportunity.

The Repriceable Promise Under Stress

The trouble is that Sun Life had spent prior quarters telling investors this business was normalizing. In May, Healy said the disability business was “moving back to more normalized levels, and we expect it to be similar to this in the future.” — David Healy, Executive · 2026-05-07 Three months later, the U.S. book produced what an analyst on the call pegged at $81 million of negative experience. That is the tension of the quarter: the same management team that had confidently called the trend benign is now asking for two to three years to price through it. Healy explained the mechanics: “the majority of the business... is effective for 1/1... these contracts are typically 2 to 3 years in duration... you would see typically affecting about 1/3 of the premium volume each year.” — David Healy, Senior Executive, Head of U.S. Health and Risk Solutions · 2026-11-05 So even if the diagnosis is right, the cure is slow. Kevin Strain added the broader context, pointing to job anxiety and a 20-year tailwind that has suddenly reversed.

I've been in this business a long time. You start to see this when you see people worried about their jobs and job loss, and that could persist for a bit of time. And it's that the fact that the whole industry is seeing it gives me more confidence in the ability to reprice, right? But that repricing will take some time, as David had talked about.
Kevin Strain, President and CEO · 2026-11-05

The keyword map reflects the urgency: pricing action and expense discipline both sit near the top of Sun Life's current keyword set, alongside severity, which spiked as a gainer. The company is leaning on the same levers it has used before — repricing, claims management, return-to-work programs, and cost control. But the market has heard this before in dental, where the fix has been slower and messier.Dental remains the cautionary tale. Management now says direct state contracts are 70% of government premium revenue, up from 55%, and commercial dental sales more than doubled. Yet the quarter's dental results were still muted, and the company expects them to stay that way. Kevin Strain had already warned in August that “the state business is going to be a struggle. It's going to be a struggle for a number of years.” — Gabriel Dechaine, Analyst or Investor · 2026-08-07 Nothing in the Q3 update contradicts that. The mental health component of disability claims, concentrated in health care and manufacturing, is a newer acute problem; the Medicaid dental mix shift is an older chronic one. Both are repriceable in theory. Both are taking longer than advertised in practice.

GreenOak: New Brand, New Margin Story

If U.S. benefits is the drag, GreenOak is the offset. Sun Life used the quarter to rebrand its private-asset platform (formerly SLC) as Greenoak, fold Bell Partners into the U.S. multifamily real estate business, and announce a strategic partnership with Wilton Re to seed a reinsurance vehicle expected to grow to USD 10 billion. Sonny Kalsi was explicit about the margin runway: “We have a target out there to get to 35% plus and we remain very confident in our ability to get there.” — Karamjit Kalsi, CEO or Senior Executive · 2026-11-05 The current FRE margin is in the high 20s, so the gap is both an opportunity and a credibility test. Integration costs are already hitting reported earnings, and management expects them to continue into 2027. The strategic logic is clear: permanent capital, fee-earning AUM, and a more institutional sales posture. The risk is that investors grade GreenOak on a shorter timeline than the integration requires.Meanwhile, MFS remains the quiet counterweight. Net outflows of USD 26.9 billion were driven by U.S. retail equity mutual funds and the industry's shift to passive. Ted Maloney was direct: “The industry dynamics really are the driver of the outflows. So every truly active manager is experiencing the same headwinds that we are in the space.” — Ted Maloney, President and CEO of MFS Investment Management · 2026-11-05 The active asset management headwind is not new, but it is persistent. Management continues to support MFS, pointing to ETF launches, fixed-income inflows, and its cash-generation role in funding buybacks. The buyback was $246 million in the quarter, partially offsetting Bell Partners share issuance.

What Changed, What Didn't

The quarter's genuinely new items are the acute U.S. LTD spike, the GreenOak brand launch, and the dividend increase. The recurring items are dental Medicaid pressure, MFS outflows, expense discipline, and the capital-return framework. A notable disappearance: after a quarter in which AI consortium ranked high in Sun Life's keyword set, the consortium language is gone. AI still appears — claims automation in Indonesia, machine learning for supplemental health — but the grand partnership narrative has been dropped. That is a small but telling shift: management is talking about operational AI, not strategic AI theatre.For investors, the central question is whether the U.S. disability spike is a cyclical blip or the start of a longer claims cycle. The Loss business — medical stop-loss — is still performing well, and Healy noted the stop-loss book's loss ratios remain in the target range. That gives Sun Life room to argue that the problem is contained to a smaller piece of U.S. employee benefits. But the company's credibility on 'repriceable' now depends on evidence: Q4 claims emergence, the 1/1/2027 renewals, and whether GreenOak's margin expansion shows up before integration costs exhaust patience. The diversification defense is real — Canada and Asia are carrying more of the growth load — but the U.S. crack is the one that will determine whether the 19% ROE and 10% EPS growth targets remain a glide path or a stretch.